Daré Bioscience, Inc.: Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection ...

Dare´ Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...
Purdue University

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

WEST LAFAYETTE, Ind. — Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will ...
Seeking Alpha

Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028

Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
MyChesCo on MSN

Traws Pharma reports phase 2 COVID-19 data, flu program update

NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) announced completion of a 90-patient Phase 2 study evaluating its ...
Seeking Alpha

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial ...
Nasdaq

Vigil Neuroscience Advances VG-3927 into Phase 2 Trial as a Promising Once-Daily Oral Therapy for Alzheimer's Disease Following Positive Phase 1 Results

Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...